Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/32230
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17759/20057 (89%)
造访人次 : 7942590      在线人数 : 602
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cnu.edu.tw/handle/310902800/32230


    標題: Evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma A single institution experience
    作者: Ke, Te-Min
    Fong, Yao
    Lin, Li-Ching
    Chien, Yu-Wun
    Yang, Ching-Chieh
    Lin, Chia-Hui
    Lin, Kuei-Li
    Que, Jenny
    貢獻者: Chi Mei Med Ctr, Dept Radiat Oncol
    Chi Mei Med Ctr, Dept Thorac Surg
    Chung Hwa Univ Med Technol, Dept Optometry
    Taipei Med Univ, Sch Med
    Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Publ Hlth
    Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Occupat & Environm Med
    Chia Nan Univ Pharm & Sci, Dept Pharm
    Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
    關鍵字: chemoradiotherapy
    esophageal squamous cell carcinoma
    radiation dose
    日期: 2018-11
    上傳時間: 2019-11-15 15:46:01 (UTC+8)
    出版者: LIPPINCOTT WILLIAMS & WILKINS
    摘要: The optimal radiation dose for definitive chemoradiotherapy in inoperable esophageal squamous cell carcinoma (ESCC) has been long debated. In this study, we evaluated the effect of doses greater than the conventional radiation dose (50.4 Gy) on tumor control, tumor response, overall survival (OS), and disease-free survival (DFS). The database of patients diagnosed with inoperable ESCC from 2007 to 2015 was obtained from the cancer registry of Chi-Mei Medical Center. All categorical variables were compared using Chi-squared test. The risk of OS and DFS were estimated using Cox proportional hazards regression, and Kaplan-Meier plots presented the trend of OS and DFS with log-rank tests used to compare differences. All significance levels were set at P<.05. A total of 84 patients were retrospectively analyzed, with 42 (50%) receiving > 50.4 Gy and 42 (50%) receiving <= 50.4 Gy (50%) concurrently with chemotherapy. Univariate and multivariate analysis revealed no significant differences between higher dose and conventional dose in OS (P=.21) and DFS (P=.26). Further dose analysis of < 50, 50 to 50.4, 51 to 60, and > 60 Gy showed no significant differences in OS or DFS. Higher doses conveyed no significant benefit on the failure pattern, either local regional failure or distant failure (P=.42). Major prognostic factors associated with better OS on multivariate analysis were stages I and II patients (P=.03) and radiation technique using arc therapy (P=.04). No acute toxicity of grade III or higher was recorded. The results of our study show that providing higher than conventional radiation doses concurrent with chemotherapy for inoperable ESCC does not impact OS or DSF, nor does it improve locoregional failure or distant failure. Although tumor response might be improved by radiation doses > 50.4 Gy, the impact on OS and DFS remain to be studied.
    link: http://dx.doi.org/10.1097/MD.0000000000013214
    關聯: Medicine, v.97, n.46, e13214
    显示于类别:[藥學系(所)] 期刊論文
    [醫務管理系(所)] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    10.1097-MD.0000000000013214.pdf469KbAdobe PDF88检视/开启
    index.html0KbHTML174检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈